Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study. (August 2017)

• Record Type: Journal Article
• Authors: Kovács, Gábor; Wachtel, Antonio; Basharova, Elena; Spinelli, Tulla; Nicolas, Pierre; Kabickova, Edita
• Is Part Of: Future oncology. Volume 13:Number 19(2017)
• Page Start: 1685
• Page End: 1698
• Publication Date: 2017-08
• Subjects: antiemetic -- chemotherapy -- palonosetron -- pediatric cancer; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0189
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: To investigate across multiple cycles the efficacy and safety of palonosetron in the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients receiving highly or moderately emetogenic chemotherapy (HEC/MEC).Patients & methods: Patients were randomly assigned to 10, 20 μg/kg palonosetron or 3 × 150 μg/kg ondansetron for up to four cycles of HEC/MEC.Results: In all on-study chemotherapy cycles, complete response rates were higher in patients in the 20 μg/kg palonosetron group than the ondansetron group. Treatment-emergent adverse events were comparable between the palonosetron 20 μg/kg and ondansetron groups.Conclusion: Over four cycles of HEC/MEC, 20 μg/kg palonosetron was an efficacious and safe treatment for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients.